Amylyx Pharmaceuticals Inc
AMLX13.980USD
+0.990+7.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
More Details of Amylyx Pharmaceuticals Inc Company
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Amylyx Pharmaceuticals Inc Info
Ticker SymbolAMLX
Company nameAmylyx Pharmaceuticals Inc
IPO dateJan 07, 2022
CEOKlee (Justin)
Number of employees123
Security typeOrdinary Share
Fiscal year-endJan 07
Address43 Thorndike Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141
Phone16176820917
Websitehttps://www.amylyx.com/
Ticker SymbolAMLX
IPO dateJan 07, 2022
CEOKlee (Justin)
Company Executives of Amylyx Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
175.76K
-6580.00%
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Ms. Gina M. Mazzariello
Ms. Gina M. Mazzariello
Chief Legal Officer and General Counsel
Chief Legal Officer and General Counsel
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
175.76K
-6580.00%
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.17%
Perceptive Advisors LLC
8.15%
Adage Capital Management, L.P.
6.21%
TCG Crossover Management, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.48%
Other
64.31%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.17%
Perceptive Advisors LLC
8.15%
Adage Capital Management, L.P.
6.21%
TCG Crossover Management, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.48%
Other
64.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.53%
Hedge Fund
33.25%
Investment Advisor/Hedge Fund
16.18%
Private Equity
9.12%
Individual Investor
7.51%
Venture Capital
3.62%
Research Firm
2.78%
Pension Fund
0.07%
Bank and Trust
0.07%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
396
113.87M
99.16%
+1.57M
2025Q3
421
112.47M
102.70%
+27.99M
2025Q2
403
84.84M
117.02%
+7.84M
2025Q1
405
77.30M
91.06%
-3.38M
2024Q4
410
53.16M
117.27%
+2.39M
2024Q3
404
54.08M
130.01%
-4.93M
2024Q2
400
54.22M
128.23%
-6.16M
2024Q1
379
60.25M
120.54%
-21.45M
2023Q4
360
66.89M
115.11%
-1.53M
2023Q3
329
65.21M
99.39%
+4.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
11.17M
10.17%
+8.12M
+266.35%
Sep 30, 2025
Perceptive Advisors LLC
8.95M
8.15%
+1.05M
+13.29%
Sep 30, 2025
Adage Capital Management, L.P.
6.82M
6.21%
-1.98M
-22.54%
Sep 30, 2025
TCG Crossover Management, LLC
6.24M
5.69%
+300.00K
+5.05%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.01M
5.48%
+1.16M
+23.95%
Sep 30, 2025
The Vanguard Group, Inc.
5.27M
4.8%
+775.72K
+17.25%
Sep 30, 2025
Commodore Capital LP
5.65M
5.14%
+1.57M
+38.63%
Nov 10, 2025
Saturn V Capital Management LP
4.60M
4.19%
+1.34M
+41.23%
Sep 30, 2025
Cohen (Joshua Barry)
3.33M
3.03%
-29.93K
-0.89%
Sep 30, 2025
Klee (Justin B)
3.33M
3.03%
-29.98K
-0.89%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.5%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco Dorsey Wright SmallCap Momentum ETF
1.15%
Invesco Dorsey Wright Healthcare Momentum ETF
1.03%
Federated Hermes MDT Small Cap Core ETF
0.51%
iShares U.S. Pharmaceuticals ETF
0.42%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Vanguard US Momentum Factor ETF
0.14%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.5%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.38%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion1.15%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.03%
Federated Hermes MDT Small Cap Core ETF
Proportion0.51%
iShares U.S. Pharmaceuticals ETF
Proportion0.42%
iShares Micro-Cap ETF
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.16%
Vanguard US Momentum Factor ETF
Proportion0.14%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
